News Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • Older
  • View All
  • Inamed to Present Study Results at Muko e.V. Annual Meeting

    From Nov 16 – 18, 2017 the 20th Annual Meeting of the German Cystic Fibrosis Society (Muko e.V.) took place. During this conference Dominik Kappeler and Irene Heimbeck presented a poster with promising results of a First-in-Patient study, involving 24 CF patients, which has been conducted at Inamed’s Clinical Unit. Read more

  • Read our latest White Paper on Clinical Trials in Diabetic patients

    What You Always Wanted to Know, But Never Dared to Ask! Diabetes is a serious chronic disease and one of the largest global health emergencies of the 21st century. Due to the risks associated with a raised blood glucose level, each type of diabetes can lead to serious complications in the heart, blood vessels, kidneys, eyes and nerves. The number of cases has steadily increased over the past few decades and has imposed a large economic burden on the global health care system. Thus, there is only one conclusion - it is important to halt the rise of diabetes and improve lives of those affected by conducting research in this area. This paper details the key points to consider when conducting a study on diabetes patients. Read more

  • Meet us at the OCT 2017

    Inamed will be exhibiting at the Outsourcing in Clinical Trials Conference taking place in Barcelona on May 16-18. We will show a variety of services ranging from in vitro device and drug characterization, to early phase clinical trials, up to clinical operations services for phase II-IV studies. Meet Inamed experts and discuss your clinical trial needs. Read more

  • Read our new complimentaty White Paper on "The importance of lung deposition studies during the development phase of inhalation products"

    Most medication intake routes are easy to control and the drug transition into the blood circulation is hardly affected by the drug uptake procedure. That, however, totally differs when choosing inhalation as route for administration. In this case the medication needs to be delivered to the target lung region as aerosol in order to interact topical in the lungs or to pass the blood-lung barrier for a systemic effect. Read more

  • Inamed talks at the German Pharm-Tox Summit 2017

    Joining one of Germany's most recognized pharmacology congresses, Inamed was honored to talk at the Germany Pharm Tox Summit, at the Workshop AGAH on Wednesday 08 March 2017. Read more

  • Read our new complimentaty White Paper on "Three major items to consider when moving from preclinical to clinical development"

    Several issues must be considered when planning the preclinical development program of a novel investigational compound such as the nature of the target, the mode of action, the choice of suitable animal models, the identification of pharmacologically effective doses levels, the design of preclinical proof-of-concept studies, and the adequate design of toxicology studies in at least two animal species that are predictive for the situation in humans, et cetera. But there are even more important aspects that are related to regulatory affairs issues. Read more

  • New Publication on Bioavailability of Different Mg-Formulations

    Besides conducting clinical trials for medicinal products or medical devices, Inamed also supports the nutrition supplement industry when it comes to specific questions in terms of comparing two products. This month a new publication became available on comparing the bioavailability of two different magnesium formulations. Read more